Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

• Status: Completed
• Trial end date: 2011-05-25
• Target enrollment: 0
• Participant gender: All

Summary

The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Apixaban; Warfarin

Criteria

Inclusion Criteria:

• Males and females ≥ 18 yrs with atrial fibrillation (AF) and one or more of the following risk factors for stroke:

• Age ≥ 75, previous stroke

• transient ischemic attack (TIA) or Systemic Embolism (SE)

• Symptomatic congestive heart failure or left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤ 40%

• Diabetes mellitus or hypertension requiring pharmacological treatment